Stock Research: DiaSorin

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

DiaSorin

BIT:DIA IT0003492391
34
  • Value
    48
  • Growth
    27
  • Safety
    Safety
    84
  • Combined
    61
  • Sentiment
    24
  • 360° View
    360° View
    34
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

DiaSorin SpA develops, produces, and commercializes reagent kits for in vitro diagnostics. The company operates in the healthcare industry, specializing in infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring, and autoimmunity. The company operates in the Immunodiagnostics and Molecular Diagnostics markets. In the last fiscal year, the company had a market cap of $5,841 million, profits of $809 million, revenue of $1,227 million, and 3271 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 34 (better than 34% compared with alternatives), overall professional sentiment and financial characteristics for the stock DiaSorin are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for DiaSorin. Only the consolidated Value Rank has an attractive rank of 84, which means that the share price of DiaSorin is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 84% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 27, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 48, meaning the company has a riskier financing structure than 52% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 76% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 24. ...read more

more
Index
MIB
Customer Focus EU
SDG 2
SDG 3
SDG 6
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
84 32 23 34
Growth
27 88 21 7
Safety
Safety
48 48 50 98
Sentiment
24 60 10 90
360° View
360° View
34 80 6 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
25 13 13 19
Opinions Change
47 50 10 64
Pro Holdings
n/a 73 31 90
Market Pulse
43 75 65 89
Sentiment
24 60 10 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
84 32 23 34
Growth
27 88 21 7
Safety Safety
48 48 50 98
Combined
61 75 6 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
83 34 33 31
Price vs. Earnings (P/E)
51 26 27 27
Price vs. Book (P/B)
78 40 37 37
Dividend Yield
63 47 39 37
Value
84 32 23 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
56 73 12 12
Profit Growth
65 83 12 54
Capital Growth
40 76 100 27
Stock Returns
3 56 18 32
Growth
27 88 21 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
46 20 22 92
Refinancing
33 53 59 71
Liquidity
54 61 53 92
Safety Safety
48 48 50 98

Similar Stocks

Discover high‑ranked alternatives to DiaSorin and broaden your portfolio horizons.

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Carrefour

ENXTPA:CA
Country: France
Industry: Hypermarkets, Super Centers
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.